Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
Publishing timestamp: 2025-02-21 15:57:12
Summary
FDA resolves shortage of Novo Nordisk's weight loss and diabetes injections, threatening compounding pharmacies. Novo Nordisk stock rises, Hims & Hers Health shares fall. FDA's decision could impact competition in the weight loss drug market.
Sentiment: MIXED
Tickers: HIMS, LLY, NVO, NOVO.B-DK,
Keywords: health care industry, pharmaceuticals, united states, hims & hers health inc, breaking news: business, lilly drn, biotech and pharmaceuticals, business, business news, biotechnology, novo nordisk a/s,